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ABSTRACT
Numerous clinical studies link cytomegalovirus (CMV) infection with incomplete posttransplantation T-cell
recovery. We hypothesized that the inability of transplant recipients to handle CMV reactivation might
correlate with a defective graft-versus-leukemia response and increased posttransplantation morbidity. Be-
tween May 1995 and August 2001, 82 patients who were CMV seropositive and survived the first 100 days after
transplantation were identified for a day 100 landmark analysis of the effect of CMV reactivation patterns on
eventual transplantation outcome. All patients underwent a myeloablative HLA-identical sibling donor T
cell–depleted stem cell transplantation with scheduled donor T-cell add-back on day 45. Median follow-up was
1032 days. Forty-two patients who had either no reactivation or only 1 positive test with quick clearance were
designated as a CMV immune competent group. Forty patients designated as CMV immune deficient (ID) had
at least 2 positive tests. Apart from younger age (33 versus 38 years; P .05) in the ID group, the 2 groups were
balanced for clinical characteristics. In multivariate analysis, ID patients had a significantly higher incidence of
leukemia relapse (58% versus 21%; P  .03) and worse disease-free survival (31% versus 66%; P  .04). There
was no significant difference in week 1 to 14 posttransplantation lymphocyte counts between the 2 groups. In
67 patients tested 3 to 6 months after transplantation, a proliferative response to CMV antigen (stimulation
index >2) occurred in 27 of 36 immune competent patients compared with 15 of 31 ID patients (P  .006).
These results show that recurrent CMV reactivation in the first 100 days after transplantation predicts for
reduced disease-free survival and increased leukemic relapse beyond 100 days and correlates with inferior
proliferative responses to CMV. The higher relapse rate may reflect poor immune reconstitution in ID patients
or an adverse effect of prolonged antiviral treatment.
© 2004 American Society for Blood and Marrow Transplantation
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bNTRODUCTION
After allogeneic stem cell transplantation (SCT)
or hematologic malignancies the quality and degree
f immune recovery in the ﬁrst few months play a d
B&MTritical role in the success or failure of the transplan-
ation. During the early phase of donor T-cell en-
raftment, transplantation outcome is largely shaped
y the degree and severity of acute graft-versus-host
isease (GVHD) and the ability of the emerging do-
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5or immune system to respond to viral infection and
esidual leukemia. After allogeneic SCT, patients pre-
iously infected with cytomegalovirus (CMV), as de-
ned by the detection of immunoglobulin G antibod-
es to CMV, have a high probability of viral
eactivation in the ﬁrst 3 months after transplantation
1-3]. Numerous clinical studies link CMV reactiva-
ion with incomplete posttransplantation T-cell re-
overy [4-9], and recent studies relate reactivation to
educed numbers of circulating CMV-speciﬁc CD4
nd CD8 T cells [10-12]. Factors that impair T-cell
ecovery, such as T-cell depletion, GVHD, and im-
unosuppression (especially with steroids), also result
n a higher rate of CMV reactivation [1]. Because most
dult patients who undergo transplantation are CMV
eropositive and because the immune response to
MV is intimately linked with T-cell reconstitution,
e hypothesized that the ability of transplant recipi-
nts to handle CMV reactivation might also predict
heir ability to mount a graft-versus-leukemia (GVL)
esponse and to withstand posttransplantation compli-
ations. In a series of patients receiving a T cell–
epleted SCT after myeloablative conditioning, 85%
f seropositive individuals reactivated CMV in the
rst 3 months after transplantation [4]. Approximately
alf of the reactivations were prolonged or recurring
nd necessitated continued treatment with ganciclo-
ir. To identify the effect of the immune response and
ntiviral treatment on later posttransplantation events,
e analyzed a cohort of 82 CMV-seropositive patients
or their CMV reactivation patterns, lymphocyte
ounts, and proliferative response to CMV antigen in
he ﬁrst 100 days. A landmark analysis showed that
rolonged CMV reactivation in the ﬁrst 100 days after
ransplantation correlated with inferior proliferative
esponses to CMV, a reduced disease-free survival
DFS), and increased leukemic relapse beyond 100
ays.
ATIENTS AND METHODS
atients
Between May 1995 and August 2001, 114 patients
nderwent a T cell–depleted SCT followed by de-
ayed add-back of donor T cells from an HLA-iden-
ical sibling donor in our institution. The study cov-
red the time period in which high-dose acyclovir
rophylaxis for CMV infection was used on all CMV-
eropositive transplant recipients [4]. Of these pa-
ients, 16 were excluded because they were CMV
eronegative. Sixteen CMV-seropositive patients died
efore day 100 after transplantation (relapse, n  5;
VHD, n  1; aspergillosis, n  2; veno-occlusive
isease, n  1; graft failure, n  1; interstitial pneu-
onitis acute respiratory distress syndrome, n  6). Aandmark analysis was performed on the remaining 82 G
0MV-seropositive patients (83% of the relevant pop-
lation) who survived beyond 100 days to evaluate the
ffect of CMV reactivation, monitored weekly until
ay 100 after transplantation, on outcome. All patients
ave written, informed consent for National Institutes
f Health protocols 93-H-0212, 94-H-0092, 94-H-
182, 95-H-0099, 97-H-0099, and 99-H-0046, ap-
roved by the National Heart, Lung, and Blood In-
titute Institutional Review Board.
In these day 100 CMV-seropositive survivors, re-
ipient ages ranged between 10 and 56 years (median,
8 years). Thirty-two were female and 50 were male.
orty-four patients with a diagnosis of chronic my-
logenous leukemia (chronic phase), acute leukemia in
rst complete remission, or myelodysplastic syndrome
efractory anemia and refractory anemia with excess
lasts subtypes were considered at standard risk for
reatment failure. The remaining 38 patients were
onsidered high risk.
reparative Regimen and SCT
Of the study group, 80 patients received a condi-
ioning regimen of fractionated total body irradiation
3.6 Gy in 8 fractions over 4 days, followed by cyclo-
hosphamide 60 mg/kg for 2 days. Busulfan 16 mg/kg
nd cyclophosphamide 200 mg/kg were given to 2
atients, who had received extensive previous radia-
ion. All patients received a CD34-selected transplant
y using elutriation (n  17), a Ceprate CellPro col-
mn (n  28), or a Nexcell Isolex 300i (Nexell Ther-
peutics, Inc., Irvine, CA; n  37) [13,14]. Seventeen
ransplants were donor bone marrow harvests, and 65
ere granulocyte colony-stimulating factor (ﬁlgras-
im; Amgen, Thousand Oaks, CA)–mobilized periph-
ral blood stem cell transplants (PBSCT), as described
reviously [15]. After transplantation, all patients re-
eived granulocyte colony-stimulating factor 5 g/kg
aily from day 7 until the neutrophil count exceeded
 109/L for 3 consecutive days.
VHD Prophylaxis
Cyclosporin A (CSA) 3 mg/kg intravenously was
tarted on day 4 until an oral dose was tolerated and
ontinued until at least day 130 after PBSCT or
onger if chronic GVHD occurred. The CSA dose was
djusted to maintain a cyclosporine plasma level of
00 to 400 ng/mL in the ﬁrst 45 patients and 100 to
00 ng/mL in the subsequent 37 patients. Because of
he low incidence of acute GVHD after T-cell deple-
ion, CSA was delayed until day 44 in the last 19
atients [16].
-Cell Add-Back
To prevent relapse and confer donor immune
unction, patients without active grade II acute
VHD received cryopreserved peripheral blood
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CMV Antigenemia Predicts Relapse Postgraft
Bononuclear cells from the donor between days 30
nd 45 and again on day 100 [17]. Depending on
evelopment of acute GVHD, cumulative doses of
dded-back lymphocytes ranged from 0 to 6  107/kg
median, 5.2  107/kg).
osttransplantation Management
All patients received ﬂuconazole from day 7 un-
il day 30 for antifungal prophylaxis. Weekly tri-
ethoprim/sulfamethoxazole was started from day 30
o day 180 as prophylaxis against Pneumocystis infec-
ion. The diagnosis and grading of acute and chronic
VHD were established according to the Seattle cri-
eria [18]. Acute GVHD grade II was treated with
orticosteroids, which were tapered according to re-
ponse.
rophylaxis and Treatment for CMV
All patients received high-dose acyclovir (500
g/m2 intravenously every 8 hours or 800 mg by
outh 4 times a day) at least to day 100 after trans-
lantation as prophylaxis against CMV and herpesvi-
us reactivation [3,19]. Blood was tested for CMV
p65 antigen (BIOSOFT CINkit; Argene Inc., North
assapequa, NY) weekly until day 100 after PBSCT
nd longer if clinically indicated. Patients also re-
eived intravenous immunoglobulin (not CMV spe-
iﬁc) at 500 mg/kg weekly until day 30 after trans-
lantation. Preemptive ganciclovir therapy was
nstituted whenever a patient developed pp65 antigen-
mia, deﬁned as at least 1 positive cell per 400 000
hite blood cells examined [3,20]. Patients received
anciclovir at an induction dose of 5 mg/kg intrave-
ously twice daily for 10 days, followed by mainte-
ance therapy at 5 mg/kg 3 times weekly, which was
ontinued until antigenemia tests remained negative
or 3 weeks. Reinduction with twice-daily dosing was
tarted at recurrence of a positive pp65 antigenemia
est. A dose of intravenous immunoglobulin (not
MV speciﬁc) at 1 g/kg was also given during the ﬁrst
eek of antigenemia and weekly at 500 mg/kg during
he period of antigenemia. Foscarnet was used for
eutropenic patients or ganciclovir-refractory cases at
he discretion of the treating physician.
CMV disease was deﬁned as the identiﬁcation of
MV in biopsy specimens from visceral sites (by cul-
ure or histology) or the detection of CMV by shell
ial culture or direct ﬂuorescent antibody stain in
ronchoalveolar lavage ﬂuid in the presence of new or
hanging pulmonary inﬁltrates. CMV retinitis was
iagnosed on retinal examination by an experienced
phthalmologist [21].
ymphocyte Count
Serial blood counts obtained by automated
ounters were analyzed. For each individual, the t
B&MTeekly median lymphocyte count was calculated from
he 3rd week (days 15-20) through the 14th week
days 91-98). Because most patients did not recover
eukocyte counts in the second week (days 7-14), the
alues for the second week (Figure 6) were derived
rom lymphocyte counts only on day 14 and not from
he median of days 7 to 14.
roliferation Assay
Heparinized venous blood or leukapheresis sam-
les from patients and donors were separated on Fi-
oll-Hypaque (Organon Teknika, Durham, NC), and
he mononuclear cells were frozen in 10% dimethyl
ulfoxide and stored in liquid nitrogen until use. The
ource of CMV antigen was heat-inactivated lysate of
ucrose density gradient–puriﬁed human CMV, strain
D169, adjusted to a protein concentration of 1.0
g/mL (Advanced Biotechnologies Inc. Columbia,
D). Staphylococcus aureus enterotoxin B (SEB) was
sed as a positive control (Sigma; St. Louis, MO). The
-cell culture medium was RPMI 1640 (Bioﬂuids,
ockville, MD) supplemented with 10% heat-inacti-
ated human AB-positive serum (Pel-Freez, Brown
eer, WI). Two hundred microliters of mononuclear
ells (1  104) in T-cell culture medium were dis-
ensed in 6 replicate wells of 96-well round-bottomed
lates and co-incubated with CMV antigen (ﬁnal con-
entration, 1 g/mL), SEB (ﬁnal concentration, 2.5
g/mL), or medium alone. After 5 days, 1 Ci of
H-thymidine was added for 16 hours; cultures were
hen harvested, and incorporation of 3H-thymidine
as determined by beta scintillation counting. Results
ere expressed as a stimulation index (SI) by dividing
he mean counts per minute incorporated by cells
xposed to CMV antigen or SEB by the mean counts
er minute of cells exposed to media alone. Samples
rom 3 healthy donors were run in every assay series to
onﬁrm proliferation conditions. An SI 2 was con-
idered to indicate a positive lymphoproliferative re-
ponse. In 53 CMV-seropositive donors and 14 sero-
egative donors, the sensitivity of the cutoff value of
I 2 was 81% (43 of 53; median, 20; range, 0.8-95),
nd the speciﬁcity was 86% (12 of 14; median, 0.9;
ange, 0.7-2.8).
tatistical Analysis
Patient characteristics in the 2 cohorts were com-
ared by using the Pearson 2 test, Mann-Whitney U
est, or Student t test where appropriate. Actuarial
robabilities of acute GVHD, relapse, survival, and
ime to the ﬁrst positive antigenemia were calculated
y the method of Kaplan and Meier [22]. Relapse in
ML was deﬁned as either cytogenetic relapse or
rank hematologic relapse. Differences between out-
omes were compared by using the log-rank test. In
he univariate analysis of risk factors for DFS and
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5elapse, the following variables were evaluated: patient
nd donor age, sex mismatch, diagnosis, type of donor,
tem cell source, GVHD prophylaxis, infused CD34
nd CD3 cell dose, and development of grade II to IV
cute GVHD. Late CMV reactivation (later than day
00) was excluded from analysis because its detection
as biased (tested only when clinically indicated) and
o permit the use the day 0 to 100 CMV reactivation
s a preexisting variable for a day 100 landmark anal-
sis. Factors found to be signiﬁcant on univariate
nalysis (P  .20) or known to be strongly predictive
f survival outcome in our transplant population were
ntered into a Cox proportional hazard model for the
ultivariate analysis of DFS and relapse probability
23].
ESULTS
MV pp65 Antigenemia
A total of 73 patients developed pp65 antigenemia.
n the ﬁrst 100 days, 33 had only 1 positive test; the
emaining 40 patients developed a second positive
est, either as persistent antigenemia (n  23; 57.5%)
r as recurrent antigenemia (n  17; 42.5%). All
econd occurrences of pp65 antigenemia were within
weeks from the ﬁrst reactivation. Twenty-one pa-
ients had positive CMV antigenemia for 2 weeks (2
ccasions), 12 were positive for 3 weeks, and the
emaining 7 patients were positive for 4 weeks or
onger (Figure 1). Forty-two patients who had either
o reactivation or only 1 positive test with quick clear-
igure 1. Histogram for number of patients in weeks of positive
ntigenemia. Forty-two patients who had either no reactivation or
nly 1 positive test are designated as CMV immune competent (IC).
he remaining 40 patients who had persistent or recurrent CMVtntigenemia are designated as CMV immune deﬁcient (ID).
2nce were designated as a CMV immune competent
IC) group. The remaining 40 patients who had per-
istent or recurrent antigenemia were designated as
he immune deﬁcient (ID) group. This grouping was
linically meaningful, because the duration of ganci-
lovir therapy was at least 1 week longer in the ID
roup and was associated with other virologic param-
ters: the actuarial probability of CMV antigenemia in
he IC group was 78.6%, compared with 100% in the
D group (P  0.00001; Figure 2), and the median
umber of positive cells at ﬁrst reactivation in 40 ID
atients was 2 (range, 1-41), compared with 1 (range,
-20) in the 33 IC patients (P  .000001; Mann-
hitneyU test; (9 patients were excluded who did not
ave reactivated CMV). Patient characteristics in the
C and ID groups are shown in Table 1. The 2 groups
ere generally well balanced for their clinical charac-
eristics, except for younger age (33 versus 38 years;
 .05) in the ID group. There was a trend for
ncreased acute GVHD in the ID group (52% versus
3%; P  0.1), which may explain the trend for a
igher total donor lymphocyte infusion dose in the IC
roup (Table 1; P  .08), because scheduled donor
ymphocyte infusions were not given to patients with
ngoing acute GVHD.
verall Transplantation Outcome
Follow-up data, including cases of CMV disease
nd causes of death, were available for all patients.
fter a median follow-up of 1032 days (range, 185-
375 days) for surviving patients, 47 patients were
live, with an actuarial survival of 52.2%  6%. Of 35
eaths, 20 were due to leukemia relapse. Of the re-
aining 15 deaths, 1 was from CMV pneumonitis, 5
rom other infectious causes (viral, n  2; bacterial,
 2; fungal, n  1), 3 from GVHD, and 6 from
ther causes (acute respiratory distress syndrome, ac-
ident at work, disseminated adenocarcinoma, late
raft rejection, Guillian-Barre´ syndrome, and post-
ransplantation lymphoproliferative disease). The ac-
igure 2. Kaplan-Meier estimates of cumulative incidence of CMV
eactivation in IC and ID groups.uarial probabilities of DFS, relapse, and nonrelapse
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CMV Antigenemia Predicts Relapse Postgraft
Bortality (1 year) were 43.4%  6%, 43.4%  7%,
nd 17%  5%, respectively. Eight patients (5 IC and
ID) developed leukemia relapse early after trans-
lantation (before day 100) and were excluded from
nalysis for DFS and relapse.
MV Antigenemia and Transplantation Outcome
In univariate analysis (n  82), there was a trend
or better overall survival (OS; 61% versus 43%; P 
15; Figure 3) and lower nonrelapse death (15% versus
3%; P  .3) in the IC group. After 8 patients were
able 1. Patient Characteristics in CMV Immune Competent and Imm
Variable
CMV
Compete
ean age (y)
ex (F/M) 1
MV status
R/D
R/D
ex mismatch
Female to male
Other combinations
onditioning regimen
Cyclophosphamide/TBI
Busulfan/cyclophosphamide
ource of stem cells
Bone marrow
Blood stem cell
iagnosis
CML-CP
CML-AP
CML-BC
AML first remission
AML other than first remission
MDS-low risk (RA, RAEB)
MDS-high risk (RAEBT or secondary)
ALL first remission
ALL other than first remission
Eosinophilic leukemia
CMMoL
Chronic lymphocytic leukemia
Multiple myeloma
Non-Hodgkin lymphoma
isease risk
Standard risk
High risk
ean CD34 cell dose (106/kg)
ean CD3 cell dose (105/kg)
otal DLI dose before day 100
<5  107/kg
>5  107/kg
cute GVHD grade II-IV 33
hronic GVHD (none/limited/extensive) 23
MV disease 2 (I
elapse before day 100
indicates recipient; D, donor; TBI, total body irradiation; CML,
BC, blastic crisis; AML, acute myelogenous leukemia; ALL, acu
MDS, myelodysplastic syndrome; RA, refractory anemia; RAE
excess blasts in transformation; DLI, donor lymphocyte infusio
No chronic GVHD versus limited or extensive chronic GVHD.une Deﬁcient Groups
Immune
nt (n  42)
CMV Immune
Deficient (n  40)
P
Value
38 33 .05
5/27 17/23 .5
36 33 .7
6 7
9 7 .7
33 33
41 39 >.9
1 1
9 8 .9
33 32
16 15
4 2
1 1
1 6
5 6
4 1
3 1
0 1
2 4
1 0
1 0
1 1
2 2
1 0
20 23 .4
22 17
4.96 5.07 .1
0.99 1.18 .38
17 24 .08
25 16
% 52% .1
/14/5 25/10/5 .6*
P, GI) 3 (liver, retinitis, GI)
5 3
chronic myelogenous leukemia; CP, chronic phase; AP, accelerated phase;
te lymphoblastic leukemia; CMMoL, chronic myelomonocytic leukemia;
B, refractory anemia with excess blasts; RAEBT, refractory anemic with
n; IP, interstitial pneumonitis; GI, gastrointestinal CMV disease.xcluded who had already relapsed before day 100, ID g
B&MTigure 3. Kaplan-Meier estimates of overall survival in IC and ID
roups.
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5as associated with a signiﬁcantly higher incidence of
eukemia relapse (58% versus 21%; P  .05) and with
orse DFS (31% versus 66%; P  0.02; Figure 4A
nd B) compared with IC. CMV antigenemia pro-
onged for 3 weeks was also associated with higher
elapse (P  .02) and a trend for worse DFS (P  .1).
able 2 summarizes the results of univariate analysis
or factors associated with relapse and DFS (n  74).
nterestingly, acute GVHD (grade II-IV) was associ-
ted with poorer DFS (P  .06) but not with relapse
P  .6). In fact, acute GVHD was signiﬁcantly asso-
iated with nonrelapse death (44% versus 5%; P 
.0001). In Cox regression analysis, persistent CMV
ntigenemia (ID) was an independent risk factor for
oth DFS and relapse (hazard ratio, 2.2 and 3.1, re-
pectively; Table 3). The differences in outcome were
ore evident in standard-risk diseases. Among the
ubset of patients with standard-risk disease (n 43 of
4), the IC group (n  20) had a signiﬁcantly better
FS (94.6% versus 33.3%; P  .001) and lower re-
apse risk (5.4% versus 50.5%; P  .03) compared
ith the ID group (n  23; Figure 5A and B). In
igh-risk patients (n  31 of 74), there was also a
rend for better DFS and lower relapse, but this did
ot reach statistical signiﬁcance (P  .25 and .48,
espectively). Assuming that steroid treatment of acute
VHD interferes with the reconstitution of immunity
o CMV, we also performed a subset analysis by ex-
luding 27 patients who had acute GVHD (grade
I-IV). Compared with the ID group (n  20), the IC
roup (n  27) had better DFS (77.5% versus 33.2%;
igure 4. Kaplan-Meier estimates of disease-free survival (A) and
lelapse (B) in IC and ID groups.
4 .01) and a lower relapse risk (19.0% versus 58.5%;
 .02).
ecovery of Lymphocyte Count
There was no signiﬁcant difference in absolute
ymphocyte counts between the IC and ID groups
hroughout the early posttransplantation period (2nd
o 14th week; Figure 6). The ID group had slightly
able 2. Univariate Analysis of Risk Factors for DFS and Relapse
n  74)
Variable
DFS %
(Actuarial)
Relapse %
(Actuarial)
isease risk
Standard (n  43) 61.1 26.4
High (n  31) 28.0 55.2
P .001 .006
ge
<38 y (n  37) 53.9 39.1
>38 y (n  37) 40.5 39.3
P .60 .51
ex match
Female to male (n  11) 40.0 13.3
Other combinations (n 
63) 48.8 40.8
P .2 .56
onor serostatus
Donor seronegative (n  13) 27.0 67.2
Donor seropositive (n  61) 52.1 30.5
P .32 .12
ource of stem cells
Bone marrow (n  16) 43.8 41.7
Peripheral blood (n  58) 45.8 39.8
P .55 .41
SA dose
Full dose 43.4 41.2
Half dose or none 59.3 36.7
P .36 .38
D34 cell dose
>4.6  106/kg (n  36) 45.9 41.0
<4.6  106/kg (n  38) 44.9 39.2
P .29 .36
D3 cell dose
>0.51  105/kg (n  37) 42.7 42.0
<0.51  105/kg (n  37) 56.0 30
P .31 .3
otal DLI dose before day 100
<5  107/kg (n  38) 56.3 24.1
>5  107/kg (n  36) 39.0 49.9
P .61 .25
MV antigenemia
>2 wk (n  37) 30.0 55.7
<2 wk (n  37) 66.3 21.0
P .02 .05
>3 wk (n  17) 18.8 73.8
<3 wk (n  57) 56.2 26.5
P .06 .02
cute GVHD (grade II-IV)
Yes (n  27) 31.1 41.7
No (n  47) 56.3 47.5
P .06 .55
LI indicates donor lymphocyte infusion.ower lymphocyte counts in weeks 8 to 11, but this did
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CMV Antigenemia Predicts Relapse Postgraft
Bot reach statistical signiﬁcance (P values were .2).
he lymphocyte counts at day 100 (14th week, greater
han, equal to, or less than the median count of 315/
L) did not inﬂuence OS, DFS, transplant-related
ortality, or relapse (P  .9, .9, .6, and .9, respec-
ively).
roliferation Assay
A total of 67 cryopreserved posttransplantation
amples—37 from IC patients and 31 from ID pa-
ients—were available for this assay. All samples were
btained before the date of leukemic relapse. Fifty-
hree of 67 samples were obtained between days 90
nd 120 after transplantation, and the remaining 14
amples were taken either between days 60 and 89 (5
amples: 3 in IC patients and 2 in ID patients) or
etween days 121 and 180 (9 samples: 3 in the IC
able 3. Risk Factors for Relapse and Death or Relapse (DFS) in Mult
Variable D
MV immune deficient HR, 2.2
igh-risk disease HR, 3.3
D34 cell dose at or above median HR, 0.7
cute GVHD grade II-IV HR, 1.1
R indicates hazard ratio; CI, conﬁdence interval.
igure 5. Subset analysis of patients with standard-risk disease:
aplan-Meier estimates of disease-free survival (A) and relapse (B)
n IC and ID groups are shown. f
B&MTroup and 6 in the ID group). A proliferative response
o CMV antigen (SI 2) occurred in 27 of 36 IC
atients compared with 15 of 31 ID patients (P .02).
he difference between the 2 groups remained signif-
cant when 2 samples that had a low SEB response (SI
2) were excluded from the analysis (27/35 in the IC
roup versus 15/30 in the ID group; P  .02). In
ontrast, there was no signiﬁcant difference in positive
nti-CMV responses between patients who had acute
VHD (n  21; 14 positive responders) or not (n 
6; 30 positive responders; P  .9). In 61 patients
hose proliferation data were available and who did
ot relapse before day 100, there was a trend for better
FS in patients who had a positive CMV response
n  40; DFS, 56.7%) compared with patients who
ad a negative response (n  21; DFS, 40.7%; P 
15). In this limited assay, we did not observe signiﬁ-
ant differences in relapse, OS, or transplant-related
ortality according to the proliferation response.
ISCUSSION
The success or failure of allogeneic SCT for leu-
emia is largely determined in the ﬁrst 6 months after
ransplantation—a period in which survival and re-
Analysis (n  74)
Relapse Relapse
CI, 1.04-4.81) HR, 3.1 (95% CI, 1.11-8.58)
.04 P  0.03
CI, 1.60-6.90) HR, 5.0 (95% CI, 1.90-13.20)
.001 P  0.001
CI, 0.34-1.46) HR, 0.5 (95% CI, 0.20-1.44)
0.3 P  0.2
CI, 0.54-2.44) HR, 0.4 (95% CI, 0.12-1.07)
0.7 P  .07
igure 6. Total lymphocyte count recovery in IC and ID groups
fter transplantation from the 2nd to the 14th week (median lym-
hocyte count, weeks 3-14). Values for the second week are derivedivariate
eath or
(95%
P 
(95%
P  0
(95%
P 
(95%
P rom day 14 lymphocyte counts only (see text).
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5apse curves show their steepest decline. Outcome is
losely linked to the reconstitution of donor immu-
ity, which inﬂuences survival through GVHD, GVL,
nd the degree of immune competence achieved
gainst infectious agents. Although thymic-dependent
mmune recovery is an important end point of post-
ransplantation immune reconstitution, it is now clear
hat such thymic tolerance is delayed and incomplete
n adult recipients [24-26]. Thus, peripheral (postthy-
ic) donor lymphocytes largely govern transplanta-
ion outcome by mediating immunity against normal
nd leukemic host tissues and infectious agents
27,28]. We chose CMV reactivation and T-cell im-
unity to CMV as a model of peripheral T-cell im-
une recovery, because CMV provides a prevalent
nd standard challenge to the immune system after
ransplantation. The ability to control CMV reactiva-
ion depends on donor immune transfer and post-
ransplantation immune reconstitution, reﬂected by
he frequency of CMV-speciﬁc T cells and their func-
ional capacity. In our CMV-seropositive patient pop-
lation, we identiﬁed 2 CMV reactivation outcomes—
atients who did not reactivate or reactivated only
nce (IC group) and those who reactivated on 2
ccasions in the ﬁrst 100 days (ID group). We used
hese characteristics to study how efﬁcient or inefﬁ-
ient handling of CMV reactivation related to CMV
mmune response at 100 days and how this behavior
orrelated with outcome beyond 3 months. Inevitably
he study design excluded CMV-seronegative patients
nd deaths in the ﬁrst 100 days. However, as far as we
ould determine, there were no obvious differences in
he mortality in IC and ID patients in this time period.
Our results show that IC patients had signiﬁcantly
ower relapse rates and improved DFS as compared
ith ID patients. In multivariate analysis, these factors
ere independent variables. IC patients had a signif-
cantly greater proliferative response to CMV antigen,
uggesting that the degree of antigenemia was in-
ersely correlated with immune competence to CMV.
ur results extend observations by the Seattle trans-
lant group, which found that high levels of CMV
NA/antigenemia and undetectable CMV-speciﬁc
-cell responses were associated with poor survival,
ttributable at least in part to CMV disease and CMV-
elated death [29]. In our series, mortality beyond 100
ays (with the exception of 1 patient) was due to causes
ther than CMV—notably, leukemic relapse. Never-
heless, a similar process of poor immune reconstitu-
ion associated with inability to eliminate CMV could
nderlie both ﬁndings.
Although it is possible to explain the relationship
etween CMV antigenemia and outcome (in particu-
ar, relapse) in immunologic terms, other explanations
hould be considered. First, the prolonged use of gan-
iclovir in the patients with persisting antigenemia
ay have caused greater myelosuppression. It is pos- t
6ible that this antiproliferative effect of ganciclovir
lso reduces immune function, either by reducing
onocytes and dendritic cells that present antigen or
y directly affecting lymphocytes [30]. Ganciclovir
ay thus have decreased the efﬁciency of the GVL
esponse and increased the risk of complications due
o infection. Second, reactivating CMV may itself be
mmunosuppressive [31]. In this case, CMV persis-
ence would be a cause rather than the result of de-
reased immune function. Finally, although this mul-
ivariate analysis identiﬁed CMV reactivation pattern
s an independent variable, it is possible that this was
surrogate for other variables not included in the
nalysis. A larger analysis with inclusion of additional
ariables would help to conﬁrm our ﬁndings.
These ﬁndings prompted us to evaluate lympho-
yte counts and lymphocyte proliferation to CMV
ntigen as a measure of immune function and a pre-
ictor of outcome. Although several analyses identify
ymphocyte counts in the ﬁrst 30 days to be predictive
f relapse [32], we did not ﬁnd day 100 lymphocyte
ounts to be predictive of later outcome. These ﬁnd-
ngs do not necessarily conﬂict: early lymphocyte re-
overy is dominated by posttransplantation natural
iller cell recovery, which may contribute to relapse
revention in the early posttransplantation phase.
ater relapse may be more linked to an antigen-
riven, T cell–mediated process. Not surprisingly, the
MV antigen proliferation assay as a functional
arker of immune function was more predictive of
ater outcome than the lymphocyte count. However,
his study was limited to a single time point and to a
roliferation assay; a cytotoxicity assay might be more
elevant in predicting the capacity of donor T cells to
xert a GVL effect.
In conclusion, our results show that monitoring
he pattern of CMV reactivation and its clearance
redicted transplantation outcome beyond 3 months.
he correlation of the CMV reactivation pattern with
n vitro proliferation to CMV antigen suggests that
MV reactivation patterns are an accurate descriptor of
he T-cell response to CMV. Furthermore, the results
aise the possibility that the quality of the T-cell immune
esponse to CMV could serve as a surrogate for deter-
ining the strength of the GVL effect.
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